Armstrong Advisory Group’s Krystal Biotech KRYS Stock Holding History

Armstrong Advisory Group’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$333	Buy	+1	New	+$346	﹤0.01%	1019

Other funds holding KRYS

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return

Armstrong Advisory Group's KRYS Position: Q3 2026 in Review

Armstrong Advisory Group opened a new position in Krystal Biotech (KRYS) in Q3 2026: 1 share worth $333. The stake represents ﹤0.01% of the portfolio and ranks #1019 among its holdings.

11 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

Armstrong Advisory Group held 1 share of Krystal Biotech worth $333 as of Q3 2026.
Krystal Biotech was a new Armstrong Advisory Group position in Q3 2026.
Krystal Biotech made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #1019 holding.
11 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.